Cefixime Capsules

1. This product is an oral third-generation cephalosporin with a broad antibacterial spectrum. It has antibacterial activity against some Gram-positive and Gram-negative bacteria, especially against Streptococcus (except Enterococcus) and Pneumococcus among Gram-positive bacteria, and gonococci, Branhamella, Escherichia coli, Klebsiella, Serratia, Proteus, and influenza bacilli among Gram-negative bacteria. Its mechanism of action is bactericidal. 2. This product has strong stability against β-lactamase produced by various bacteria, and shows excellent antibacterial activity against bacteria producing β-lactamase. 3. The mechanism of action of this product is to prevent the synthesis of bacterial cell walls. Its action point varies depending on the type of bacteria. It has a high affinity with 1 (1a, 1b, 1c) and 3 in penicillin binding protein (PBP).

The main ingredient of this product is cefixime.

The content of this product is white to light yellow powder or granules

This product is suitable for the following bacterial infectious diseases caused by Streptococcus (except enterococci), pneumococcus, gonococcus, Branhamella catarrhalis, Escherichia coli, Klebsiella, Serratia, Proteus and influenza bacilli: 1. Bronchitis, bronchiectasis (when infected), secondary infection of chronic respiratory system infections, pneumonia; 2. Pyelonephritis, cystitis, gonococcal urethritis; 3. Cholecystitis, cholangitis; 4. Scarlet fever; 5. Otitis media, sinusitis.

1. Adults and children weighing more than 30 kg: Oral, 100 mg (1 tablet) each time, twice a day. For adults with severe infection, the dose can be increased to 200 mg (2 tablets) each time, twice a day. 2. Oral, 1.5~3 mg/kg per dose, twice a day. Or follow the doctor's advice.

Clinical research data show that the main adverse reactions of this product include gastrointestinal reactions such as diarrhea (0.87%), skin symptoms such as rash (0.23%), and abnormal clinical examination values (including increased GPT (0.61%), increased GOT (0.45%), eosinophilia (0.20%), etc.). The details are as follows: 1. Serious adverse reactions: (1) Shock: Shock may occur ((2) Allergic symptoms: Allergic-like symptoms may occur (including dyspnea, systemic flushing, angioedema, urticaria, etc.) ((3) Skin lesions: Skin mucosal eye syndrome (Stevens-Johnson syndrome (0.1%), toxic epidermal necrolysis (i.e. Lyell syndrome, (4) Blood disorders: Agranulocytosis may occur ((5) Renal dysfunction: Acute renal insufficiency and other serious renal dysfunction may occur ((6) Colitis: Severe colitis with bloody stools such as pseudomembranous colitis may occur ((7) Interstitial pneumonia may occur (Fever, cough may occur Other adverse reactions (1) Allergic reactions: rash, urticaria, erythema (0.1-(2) Blood: eosinophilia (0.1-(3) Liver: increased GOT, increased GPT, increased AL-P (0.1-(4) Kidney: increased BUN ((5) Digestive system: diarrhea, stomach discomfort (0.1-(6) Dysbacteriosis: stomatitis, oral candidiasis ((7) Vitamin deficiency: vitamin K deficiency (hypoprothrombinemia, bleeding tendency, etc.), vitamin B deficiency (glossitis, stomatitis, loss of appetite, neuritis, etc.) ((8) Others: headache, dizziness (

Those who are allergic to this product or other cephalosporin antibiotics.

Precautions for children: The safety of the drug for newborns and premature infants has not been established (no experience of use). Precautions for pregnancy and lactation: The safety and effectiveness of this drug for pregnant women have not been established. Use this drug only when it is necessary. It is not clear whether this drug is secreted from breast milk. If it must be used, breastfeeding should be suspended. Precautions for the elderly: Reduce the dosage for elderly patients.

Carbamazepine: When combined with this product, it can cause an increase in carbamazepine levels. If it must be used together, the concentration of carbamazepine in plasma should be monitored. Warfarin and anticoagulants: When used in combination with this product, prothrombin recovery time is increased.

Keep in a dark, sealed container, and stored in a cool, dark (no more than 20°C) dry place.

0.1 g

24 months

Jinri Pharmaceutical (China) Co., Ltd.

• Founded in:

  1991-07-05

• Address:

  Jinri Industrial Village, Jinri Road, Tongan District, Xiamen

• Tax NO.:

  91350200612009145K

• Registered Funds:

  225.5 million yuan

• Website:

  Log in to view

• Email:

  Log in to view